Rho GTPase-Activating Protein 45 (ARHGAP45) Antibody

Product Graph
312€ (60 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Rho GTPase-Activating Protein 45 (ARHGAP45) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx125534
tested applications
WB

Description

ARHGAP45 Antibody is a Rabbit Polyclonal against ARHGAP45.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Rho GTPase-Activating Protein 45 (ARHGAP45)
Host
Rabbit
Reactivity
Human, Rat
Recommended Dilution
WB: 1/500 - 1/2000. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Isotype
IgG
Purification
Purified by affinity chromatography.
Size 1
60 µl
Size 2
120 µl
Size 3
200 µl
Form
Liquid
Tested Applications
WB
Buffer
PBS, pH 7.3, containing 0.02% sodium azide, 50% glycerol.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
Q92619
Gene ID
23526
NCBI Accession
NP_036424.2
Background
Antibody anti-ARHGAP45
Status
RUO
Note
Concentration: 1 mg/ml -

Descripción

Related Products

FNab03935

ARHGAP45 antibody

GTPase activator for the Rho-type GTPases. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens(mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease(GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation(BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte(CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.

Ver Producto
abx113024

Rho GTPase Activating Protein 45 (ARHGAP45) Antibody

Histocompatibility (Minor) Ha-1 Antibody is a Rabbit Polyclonal antibody against Histocompatibility (Minor) Ha-1.

Ver Producto
abx125534

Rho GTPase-Activating Protein 45 (ARHGAP45) Antibody

ARHGAP45 Antibody is a Rabbit Polyclonal against ARHGAP45.

Ver Producto